Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and in vitro experiments
- Authors:
- He Pang
- Hang Wu
- Zeyu Zhan
- Tingrui Wu
- Min Xiang
- Zhiyan Wang
- Lijun Song
- Bo Wei
-
Affiliations: Orthopedics Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China, Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China, Reproductive Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China - Published online on: December 28, 2023 https://doi.org/10.3892/or.2023.8692
- Article Number: 33
-
Copyright: © Pang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
|
Karadurmus N, Sahin U, Bahadir Basgoz B and Demirer T: Is there a role of high dose chemotherapy and autologous stem cell transplantation in the treatment of Ewing's sarcoma and osteosarcomas? J BUON. 23:1235–1241. 2018.PubMed/NCBI | |
|
Zhu T, Han J, Yang L, Cai Z, Sun W, Hua Y and Xu J: Immune microenvironment in osteosarcoma: Components, therapeutic strategies and clinical applications. Front Immunol. 13:9075502022. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng C, Tang F, Min L, Hornicek F, Duan Z and Tu C: PTEN in osteosarcoma: Recent advances and the therapeutic potential. Biochim Biophys Acta Rev Cancer. 1874:1884052020. View Article : Google Scholar : PubMed/NCBI | |
|
Cortini M, Avnet S and Baldini N: Mesenchymal stroma: Role in osteosarcoma progression. Cancer Lett. 405:90–99. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mutsaers A and Walkley C: Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells? Bone. 62:56–63. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cascini C and Chiodoni C: The immune landscape of osteosarcoma: Implications for prognosis and treatment response. Cells. 10:16682021. View Article : Google Scholar : PubMed/NCBI | |
|
Ghafouri-Fard S, Shirvani-Farsani Z, Hussen B and Taheri M: The critical roles of lncRNAs in the development of osteosarcoma. Biomed Pharmacother. 135:1112172021. View Article : Google Scholar : PubMed/NCBI | |
|
Osborne T and Khanna C: A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol. 146:132–142. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Xie L, Ren T, Huang Y, Xu J and Guo W: Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 500:1–10. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Prudowsky Z and Yustein J: Recent insights into therapy resistance in osteosarcoma. Cancers (Basel). 13:832020. View Article : Google Scholar : PubMed/NCBI | |
|
Berner K, Johannesen TB, Berner A, Haugland HK, Bjerkehagen B, Bøhler PJ and Bruland ØS: Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. Acta Oncol. 54:25–33. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Grinberg S, Posta A, Weber K and Wilson R: Limb salvage and reconstruction options in osteosarcoma. Adv Exp Med Biol. 1257:13–29. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bielack S, Jürgens H, Jundt G, Kevric M, Kühne T, Reichardt P, Zoubek A, Werner M, Winkelmann W and Kotz R: Osteosarcoma: The COSS experience. Cancer Treat Res. 152:289–308. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bielack S, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R, Exner GU, Franzius C, Lang S, Maas R, et al: Skip metastases in osteosarcoma: Experience of the cooperative osteosarcoma study group. J Clin Oncol. 24:1535–1541. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Lou Y, Wang J, Yu C and Shen W: Research status and molecular mechanism of the traditional chinese medicine and antitumor therapy combined strategy based on tumor microenvironment. Front Immunol. 11:6097052020. View Article : Google Scholar : PubMed/NCBI | |
|
Mioc M, Milan A, Malița D, Mioc A, Prodea A, Racoviceanu R, Ghiulai R, Cristea A, Căruntu F and Șoica C: Recent advances regarding the molecular mechanisms of triterpenic acids: A review (Part I). Int J Mol Sci. 23:77402022. View Article : Google Scholar : PubMed/NCBI | |
|
Hong G, Zhou L, Han X, Sun P, Chen Z, He W, Tickner J, Chen L, Shi X and Xu J: Asiatic acid inhibits OVX-induced osteoporosis and osteoclastogenesis regulating RANKL-mediated NF-κb and Nfatc1 signaling pathways. Front Pharmacol. 11:3312020. View Article : Google Scholar : PubMed/NCBI | |
|
Sycz Z, Tichaczek-Goska D and Wojnicz D: Anti-planktonic and Anti-biofilm properties of pentacyclic triterpenes-asiatic acid and ursolic acid as promising antibacterial future pharmaceuticals. Biomolecules. 12:982022. View Article : Google Scholar : PubMed/NCBI | |
|
Songvut P, Chariyavilaskul P, Tantisira M and Khemawoot P: Safety and pharmacokinetics of standardized extract of centella asiatica (ECa 233) Capsules in healthy thai volunteers: A phase 1 clinical study. Planta Med. 85:483–490. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Palmer N and Kaldis P: Less-well known functions of cyclin/CDK complexes. Semin Cell Dev Biol. 107:54–62. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jirawatnotai S, Dalton S and Wattanapanitch M: Role of cyclins and cyclin-dependent kinases in pluripotent stem cells and their potential as a therapeutic target. Semin Cell Dev Biol. 107:63–71. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Jin W, Zhu S, Chen Y and Liu B: Targeting regulated cell death (RCD) with small-molecule compounds in cancer therapy: A revisited review of apoptosis, autophagy-dependent cell death and necroptosis. Drug Discov Today. 27:612–625. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Morana O, Wood W and Gregory C: The apoptosis paradox in cancer. Int J Mol Sci. 23:13282022. View Article : Google Scholar : PubMed/NCBI | |
|
Carneiro B and El-Deiry WS: Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 17:395–417. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fulda S: Targeting extrinsic apoptosis in cancer: Challenges and opportunities. Semin Cell Dev Biol. 39:20–25. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tan Y, Zhang X, Zhang S, Zhu T, Garg M, Lobie PE and Pandey V: Mitochondria: The metabolic switch of cellular oncogenic transformation. Biochim Biophys Acta Rev Cancer. 1876:1885342021. View Article : Google Scholar : PubMed/NCBI | |
|
Noguchi M, Hirata N, Tanaka T, Suizu F, Nakajima H and Chiorini J: Autophagy as a modulator of cell death machinery. Cell Death Dis. 11:5172020. View Article : Google Scholar : PubMed/NCBI | |
|
Gerada C and Ryan K: Autophagy, the innate immune response and cancer. Mol Oncol. 14:1913–1929. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Braicu C, Zanoaga O, Zimta AA, Tigu AB, Kilpatrick KL, Bishayee A, Nabavi SM and Berindan-Neagoe I: Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells. Semin Cancer Biol. 80:218–236. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
du Plessis M, Davis T, Loos B, Pretorius E, de Villiers W and Engelbrecht A: Molecular regulation of autophagy in a pro-inflammatory tumour microenvironment: New insight into the role of serum amyloid A. Cytokine Growth Factor Rev. 59:71–83. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Jing Y, Liang W, Liu J, Zhang L, Wei J, Yang J, Zhang Y and Huang Z: Autophagy-mediating microRNAs in cancer chemoresistance. Cell Biol Toxicol. 36:517–536. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Miller D and Thorburn A: Autophagy and organelle homeostasis in cancer. Dev Cell. 56:906–918. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ning B, Liu Y, Huang T and Wei Y: Autophagy and its role in osteosarcoma. Cancer Med. 12:5676–5687. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Das C, Banerjee I and Mandal M: Pro-survival autophagy: An emerging candidate of tumor progression through maintaining hallmarks of cancer. Semin Cancer Biol. 66:59–74. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Long M and McWilliams T: Monitoring autophagy in cancer: From bench to bedside. Semin Cancer Biol. 66:12–21. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta R, Ambasta R and Pravir K: Autophagy and apoptosis cascade: Which is more prominent in neuronal death? Cell Mol Life Sci. 78:8001–8047. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 8:e30152017. View Article : Google Scholar : PubMed/NCBI | |
|
Hao DC and Xiao P: Network pharmacology: A Rosetta stone for traditional Chinese medicine. Drug Dev Res. 75:299–312. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Stanzione F, Giangreco I and Cole J: Use of molecular docking computational tools in drug discovery. Prog Med Chem. 60:273–343. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bock FJ and Tait SWG: Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 21:85–100. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
42. Mariño G, Niso-Santano M, Baehrecke E and Kroemer G: Self-consumption: The interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 15:81–94. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Su Z, Yang Z, Xu Y, Chen Y and Yu Q: Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 14:482015. View Article : Google Scholar : PubMed/NCBI | |
|
Ritter J and Bielack S: Osteosarcoma. Ann Oncol. 21 (Suppl 7):vii320–vii325. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
A sleeping beauty screen highlights cancer drivers in osteosarcoma. Cancer Discov. 5:6902015. View Article : Google Scholar | |
|
Spalato M and Italiano A: The safety of current pharmacotherapeutic strategies for osteosarcoma. Expert Opin Drug Safety. 20:427–438. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sevelda F, Mayr L, Kubista B, Lötsch D, van Schoonhoven S, Windhager R, Pirker C, Micksche M and Berger W: EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. J Exp Clin Cancer Res. 34:1342015. View Article : Google Scholar : PubMed/NCBI | |
|
Kato S, Lippman S, Flaherty K and Kurzrock R: The conundrum of genetic ‘Drivers’ in benign conditions. J Natl Cancer Inst. 108:djw0362016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Zhao HF, Yao TF and Gong H: Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. Invest New Drugs. 37:175–183. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wan Z, Huang S, Mo F, Yao Y, Liu G, Han Z, Chen M and Zhiyun L: CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis. Exp Cell Res. 384:1116462019. View Article : Google Scholar : PubMed/NCBI | |
|
Kersting C, Gebert C, Agelopoulos K, Schmidt H, van Diest PJ, Juergens H, Winkelmann W, Kevric M, Gosheger G, Brandt B, et al: Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res. 13:2998–3005. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang SL, Zhong GX, Wang XW, Yu FQ, Weng DF, Wang XX and Lin JH: Prognostic significance of the expression of HER family members in primary osteosarcoma. Oncol Lett. 16:2185–2194. 2018.PubMed/NCBI | |
|
Yadav P, Yadav R, Jain S and Vaidya A: Caspase-3: A primary target for natural and synthetic compounds for cancer therapy. Chem Biol Drug Des. 98:144–165. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Chen C, Chen C, Wu P and Chen WM: Suppression of estrogen receptor alpha inhibits cell proliferation, differentiation and enhances the chemosensitivity of P53-positive U2OS osteosarcoma cell. Int J Mol Sci. 22:112382021. View Article : Google Scholar : PubMed/NCBI | |
|
Taipale M, Jarosz D and Lindquist S: HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat Rev Mol Cell Biol. 11:515–528. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Peng Y, Yang Z, Zhang H, Xu C, Liu L, Zhao Q, Wu J, Wang H and Liu J: DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer. BMC Cancer. 22:5612022. View Article : Google Scholar : PubMed/NCBI | |
|
Chu S, Liu Y, Zhang L, Liu B and Li L, Shi JZ and Li L: Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Mol Biol Rep. 40:1–6. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao X, Wang W, Li Y, Yang D, Li X, Shen C, Liu Y, Ke X, Guo S and Guo Z: HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res. 37:2012018. View Article : Google Scholar : PubMed/NCBI | |
|
Szulc-Kielbik I, Kielbik M, Nowak M and Klink M: The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Biochim Biophys Acta Rev Cancer. 1876:1886392021. View Article : Google Scholar : PubMed/NCBI | |
|
Tzeng HE, Tsai CH, Chang ZL, Su CM, Wang SW, Hwang WL and Tang CH: Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol. 85:531–540. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Itoh H, Kadomatsu T, Tanoue H, Yugami M, Miyata K, Endo M, Morinaga J, Kobayashi E, Miyamoto T, Kurahashi R, et al: TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma. Oncogene. 37:2903–2920. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Ma K and Li WY: IL-6 promotes cancer stemness and oncogenicity in U2OS and MG-63 Osteosarcoma Cells by Upregulating the OPN-STAT3 pathway. J Cancer. 10:6511–6525. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Parkin A, Man J, Timpson P and Pajic M: Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: From mechanism to therapy. FEBS J. 286:3510–3539. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z, Xie J, Fang J, Lv M, Yang M, Deng Z, Xie Y and Cai L: Nigericin exerts anticancer effects through inhibition of the SRC/STAT3/BCL-2 in osteosarcoma. Biochem Pharmacol. 198:1149382022. View Article : Google Scholar : PubMed/NCBI | |
|
Urciuoli E, Coletta I, Rizzuto E, De Vito R, Petrini S, D'Oria V, Pezzullo M, Milano GM, Cozza R, Locatelli F and Peruzzi B: Src nuclear localization and its prognostic relevance in human osteosarcoma. J Cell Physiol. 233:1658–1670. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao G, Gao Z, Zhang Q, Tang XF, Lv YF, Zhang ZS, Zhang Y, Tan QL, Peng DB, Jiang DM and Guo QN: TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis. J Exp Clin Cancer Res. 37:1882018. View Article : Google Scholar : PubMed/NCBI | |
|
Klein MJ: Cyclin-dependent kinase inhibition: An opportunity to target protein-protein interactions. Adv Protein Chem Struct Biol. 121:115–141. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zou T and Lin Z: The involvement of ubiquitination machinery in cell cycle regulation and cancer progression. Int J Mol Sci. 22:57542021. View Article : Google Scholar : PubMed/NCBI | |
|
Han C, Wang Z, Chen S, Li L, Xu Y, Kang W, Wei C, Ma H, Wang M and Jin X: Berbamine suppresses the progression of bladder cancer by modulating the ROS/NF-κ B axis. Oxid Med Cell Longev. 2021:88517632021. View Article : Google Scholar : PubMed/NCBI | |
|
Fischer M and Müller GJ: Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Crit Rev Biochem Mol Biol. 52:638–662. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Huang C, Yang P, Li C and Li M: Eldecalcitol induces apoptosis and autophagy in human osteosarcoma MG-63 cells by accumulating ROS to suppress the PI3K/Akt/mTOR signaling pathway. Cell Signal. 78:1098412021. View Article : Google Scholar : PubMed/NCBI | |
|
Wirries A, Jabari S, Jansen EP, Roth S, Figueroa-Juárez E, Wissniowski TT, Neureiter D, Klieser E, Lechler P, Ruchholtz S, et al: Panobinostat mediated cell death: A novel therapeutic approach for osteosarcoma. Oncotarget. 9:32997–33010. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mickymaray S, Alfaiz FA, Paramasivam A, Veeraraghavan VP, Periadurai ND, Surapaneni KM and Niu G: Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway. Saudi J Biol Sci. 28:3641–3649. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tung FI, Chen LC, Wang YC, Chen MH, Shueng PW and Liu TY: Using a hybrid radioenhancer to discover tumor cell-targeted treatment for osteosarcoma: An in vitro study. Curr Med Chem. 28:3877–3889. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Burke PJ: Mitochondria, bioenergetics and apoptosis in cancer. Trends Cancer. 3:857–870. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Praharaj PP, Naik PP, Panigrahi DP, Bhol CS, Mahapatra KK, Patra S, Sethi G and Bhutia SK: Intricate role of mitochondrial lipid in mitophagy and mitochondrial apoptosis: Its implication in cancer therapeutics. Cell Mol Life Sci. 76:1641–1652. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gibson CJ and Davids MS: BCL-2 antagonism to target the intrinsic mitochondrial pathway of apoptosis. Clin Cancer Res. 21:5021–5029. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shoshan-Barmatz V, Shteinfer-Kuzmine A and Verma A: VDAC1 at the intersection of cell metabolism, apoptosis, and diseases. Biomolecules. 10:14852020. View Article : Google Scholar : PubMed/NCBI | |
|
Shoshan-Barmatz V, Krelin Y and Chen Q: VDAC1 as a player in mitochondria-mediated apoptosis and target for modulating apoptosis. Curr Med Chem. 24:4435–4446. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shoshan-Barmatz V, De S and Meir A: The mitochondrial voltage-dependent anion channel 1, Ca2+ transport, apoptosis, and their regulation. Front Oncol. 7:602017. View Article : Google Scholar : PubMed/NCBI | |
|
Shoshan-Barmatz V, Krelin Y, Shteinfer-Kuzmine A and Arif T: Voltage-dependent anion channel 1 as an emerging drug target for novel anti-cancer therapeutics. Front Oncol. 7:1542017. View Article : Google Scholar : PubMed/NCBI | |
|
Xia H, Green D and Zou W: Autophagy in tumour immunity and therapy. Nat Rev Cancer. 21:281–297. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Levy J, Towers C and Thorburn A: Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jacquet M, Guittaut M, Fraichard A and Despouy G: The functions of Atg8-family proteins in autophagy and cancer: Linked or unrelated? Autophagy. 17:599–611. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Heckmann BL and Green DR: LC3-associated phagocytosis at a glance. J Cell Sci. 132:2019. View Article : Google Scholar | |
|
Moscat J, Karin M and Diaz-Meco MT: p62 in cancer: Signaling adaptor beyond autophagy. Cell. 167:606–609. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW and Li B: Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 6:4252021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Yu X, Yan Y, Wang C and Wang WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M, Liu F, Li YJ, Yin JN, Gao YL, Wang XY, Yang C, Liu JG and Li HJ: Ginsenoside Rg5 inhibits human osteosarcoma cell proliferation and induces cell apoptosis through PI3K/Akt/mTORC1-Related LC3 autophagy pathway. Oxid Med Cell Longev. 2021:50403262021.PubMed/NCBI | |
|
Angulo P, Kaushik G, Subramaniam D, Dandawate P, Neville K, Chastain K and Anant S: Natural compounds targeting major cell signaling pathways: A novel paradigm for osteosarcoma therapy. J Hematol Oncol. 10:102017. View Article : Google Scholar : PubMed/NCBI | |
|
Khezri MR, Jafari R, Yousefi K and Zolbanin NM: The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Exp Mol Pathol. 127:1047872022. View Article : Google Scholar : PubMed/NCBI | |
|
Rezatabar S, Karimian A, Rameshknia V, Parsian H, Majidinia M, Kopi TA, Bishayee A, Sadeghinia A, Yousefi M, Monirialamdari M and Yousefi B: RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression. J Cell Physiol. 234:14951–14965. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner E and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ding S, Pang ZY, Chen XM, Li Z, Liu XX, Zhai QL, Huang JM and Ruan ZY: Urolithin a attenuates IL-1β-induced inflammatory responses and cartilage degradation via inhibiting the MAPK/NF-κB signaling pathways in rat articular chondrocytes. J Inflamm (Lond). 17:132020. View Article : Google Scholar : PubMed/NCBI | |
|
Lv H, Zhen C, Liu J and Shang PJ: β-Phenethyl isothiocyanate induces cell death in human osteosarcoma through altering iron metabolism, disturbing the redox balance, and activating the MAPK signaling pathway. Oxid Med Cell Longev. 2020:50219832020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu J, Yu W, Liu B, Wang Y, Shao J, Wang J, Xia K, Liang C, Fang W, Zhou C and Tao H: Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death Dis. 8:e31132017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Han D, Liu T, Huang C, Hu Z, Tan X and Wu S: Asiatic acid improves high-fat-diet-induced osteoporosis in mice via regulating SIRT1/FOXO1 signaling and inhibiting oxidative stress. Histol Histopathol. 37:769–777. 2022.PubMed/NCBI | |
|
Huang X, Zuo L, Lv Y, Chen C, Yang Y, Xin H, Li Y and Qian Y: Asiatic acid attenuates myocardial ischemia/reperfusion injury via Akt/GSK-3β/HIF-1α signaling in rat H9c2 cardiomyocytes. Molecules. 21:12482016. View Article : Google Scholar : PubMed/NCBI | |
|
Qi Z, Ci X, Huang J, Liu Q, Yu Q, Zhou J and Deng X: Asiatic acid enhances Nrf2 signaling to protect HepG2 cells from oxidative damage through Akt and ERK activation. Biomed Pharmacother. 88:252–259. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Yao J, Zou C, Zhang H, Zhang S, Liu J, Ma G, Jiang P and Zhang W: Asiatic acid protects against hepatic ischemia/reperfusion injury by inactivation of Kupffer cells via PPARγ/NLRP3 inflammasome signaling pathway. Oncotarget. 8:86339–86355. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dutta S, Chakraborty P, Basak S, Ghosh S, Ghosh N, Chatterjee S, Dewanjee S and Sil PC: Synthesis, characterization, and evaluation of in vitro cytotoxicity and in vivo antitumor activity of asiatic acid-loaded poly lactic-co-glycolic acid nanoparticles: A strategy of treating breast cancer. Life Sci. 307:1208762022. View Article : Google Scholar : PubMed/NCBI | |
|
Wu T, Geng J, Guo W, Gao J and Zhu XJ: Asiatic acid inhibits lung cancer cell growth in vitro and in vivo by destroying mitochondria. Acta Pharm Sin B. 7:65–72. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Park B, Bosire K, Lee E, Lee Y and Kim JJ: Asiatic acid induces apoptosis in SK-MEL-2 human melanoma cells. Cancer Lett. 218:81–90. 2005. View Article : Google Scholar : PubMed/NCBI |
